# Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

> **NCT05377034** · PHASE2 · RECRUITING · sponsor: **National Cancer Centre, Singapore** · enrollment: 100 (estimated)

## Conditions studied

- Locally Advanced Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** SIRT-Y90 with Atezolizumab + Bevacizumab
- **COMBINATION_PRODUCT:** SIRT-Y90 with Placebo (IV)

## Key facts

- **NCT ID:** NCT05377034
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-26
- **Primary completion:** 2026-07-25
- **Final completion:** 2028-01-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05377034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05377034, "Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05377034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*